Boehringer Ingelheim has received approval from the European Commission for Praxbind (idarucizumab), a treatment designed to quickly reverse the anticoagulant effects.Ingelheim, Germany, 20 June, 2014 – Boehringer Ingelheim today announces a new study of Pradaxa® (dabigatran etexilate) in patients with atrial fibrillation (AF).